Organ TransplantationNCT06652919
Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients
An observational study of Organ Transplantation, run by Universität Münster at 1 site in Germany.
Trial summary
The aim of this study is to collect feedback from organ transplant patients or their caregivers/relatives on the medication information leaflets we've developed, using a questionnaire, and to adjust the content to better meet the specific needs of this unique patient group. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Organ Transplantation
- How many people
- 30 participants
- Where
- 1 siteGermany
- Study dates
- 6 Nov 2024to Mar 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients who have undergone solid organ transplantation (kidney, liver, heart, lung) or their caregivers/family members
Who may be able to join
- Patients who have undergone solid organ transplantation (kidney, liver, heart, lung)
- Caregivers or family members of organ transplant patients
- German-speaking individuals
- adult
Who cannot join
- Individuals who are not able to provide consent
- Non-German-speaking individuals
- under 18 years old
- Patients who have undergone organ transplantation and are no longer taking immunosuppressants
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
Institute of Pharmaceutical and Medicinal Chemistry, Clinical Pharmacy, University of Münster
Münster, North Rhine-Westphalia, 48149
Georg Hempel, Prof. Dr., +49 251 83-33334, georg.hempel@uni-muenster.de
Li-Yun Chen
About this study
Official title: Development and Validation of Materials for the Pharmaceutical Care of Organ Transplant Recipients in Community Pharmacy: Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients
The aim of this study is to collect feedback from organ transplant patients or their caregivers/relatives on the medication information leaflets we've developed, using a questionnaire, and to adjust the content to better meet the specific needs of this unique patient group.
Read the detailed description
Introduction:
Organ transplantation is a life-saving procedure, but it also marks the beginning of a lifelong journey for patients. In 2023 alone, over 3,600 organ transplants were performed in Germany, with kidney, liver, heart, and lung transplants being the most common. Following a transplant, patients must take a combination of immunosuppressive medications to prevent their body from rejecting the new organ. These drugs, while essential, come with significant risks. Many of which have a very narrow therapeutic range and a high risk of drug interactions. Additionally, these medications have unique side effects that can affect mortality and health-related quality of life (HRQOL). As a result, organ transplant patients require constant medical monitoring and comprehensive education about their medications to ensure long-term graft survival and a better quality of life.
Community pharmacies in Germany have recognized the need to support these patients. Since 2022, community pharmacies have been offering pharmaceutical care services specifically tailored to organ transplant recipients, focusing on safe medication use and personalized counseling, including brown-bag reviews. This service is covered by health insurance and aims to reduce administration errors, improve therapy adherence, and enhance overall patient safety. However, despite nearly 4,000 new organ transplants each year, only a small fraction of these patients-less than 3%-benefit from these services annually. The reality is that public pharmacies rarely interact with transplant patients, as they make up a small group. Furthermore, there is currently a lack of adequate materials to support the provision of this service for transplant patients.
This research project addresses this gap by developing and validating specific materials that will help pharmacies deliver high-quality pharmaceutical care to organ transplant recipients. A key element of this project is the medication information leaflets designed by the investigators, which aim to enhance patients' understanding of their immunosuppressive therapy, reduce medication use errors, and ultimately improve medication safety.
The aim of this study is to collect feedback from organ transplant patients or their caregivers/relatives on these medication leaflets, using a questionnaire instrument called "Adapted Consumer Information Rating Form (CIRF)", developed by Krass et al. The results will help the investigators evaluate the quality of the medication information leaflets in terms of their content and design. This will also assist the investigators in adjusting the content to better meet the specific needs of this unique patient group in the future.
Study design:
This pilot study is designed as a descriptive survey. It involves a one-time survey, either online or in paper form, that collects data on participants' evaluations and opinions regarding the medication information sheets. The instrument that is used, the original Adapted CIRF, was initially translated by the investigators through a peer review process, including cultural adaptation from English to German. After two rounds of peer review, the final version was produced. Permission for the use and translation of the original Adapted CIRF was obtained from Krass et al. Additionally, demographic data will be collected in the study. This study was approved by the Ethics Committee: Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster.
The recruitment of the participants will be conducted through cooperating pharmacies and patient self-help groups, and participation in the questionnaire is voluntary. Data protection measures will be taken into account to ensure the confidentiality and security of participants' information.
Procedure for participation in the study:
- The study begins as soon as the participants have agreed to the consent form.
- The study consists of two parts. In Part 1, participants are asked to select a medication information sheet and thoroughly read it.
- In Part 2, participants will ask to complete the questionnaire.
- After completing the questionnaire, the participation is considered finished. The process will take approximately 10 to 20 minutes.
- Conditions
- Organ Transplantation
- Keywords
- Organ transplantation, Consumer Information Rating Form, Pharmaceutical Care, Community Pharmacy, Patient Information Leaflets
What is being measured
The primary outcome is the main question the study is designed to answer.
Consumer Information Rating Form (CIRF): Mean "comprehensibility" score, mean "future use" score, mean "utility" score and mean "design quality" score.
In this research, the measurement instrument called the Consumer Information Rating Form (CIRF) is used, though the content has been slightly adapted to fit our study. It was developed as a direct method for quantifying consumers' perceptions of written patient information, including their views on its comprehensibility, utility, and overall design quality.
In the questionnaire, four perspectives will be evaluated using Likert scales, including "comprehensibility" (5 items, with a total score range from 5 to 25), "future use" (3 items, with a total score range from 3 to 15), "utility" (5 topics with two perspectives: the amount of information provided and its usefulness, with a total score range from 3 to 20.), and "design quality" (6 items, with a total score range from 6 to 30). Higher scores indicate better quality of the patient information leaflet.
Measured: 3 months
Participants' characteristics
Gender, age group, highest level of education, current employment status, if participant has worked in the healthcare system, Which patient information leaflet did the participant evaluate? What type of organ transplant has the participant or the person they look after received? (Kidney, liver, heart, or lung transplant), How long has it been since the transplant?
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2024
- Study start6 Nov 2024 (estimated)
- Primary completionJan 2025 (estimated)
- Study completionMar 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Organ TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universität Münster
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Li-Yun Chen, Universität Münster
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06652919
- Sponsor's protocol ID
- Clinical Pharmacy Uni MS_2024
- Status last verified
- Nov 2024
- First submitted
- 16 Oct 2024
- Last updated
- 8 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Validation of Materials for the Pharmaceutical Care of Organ Transplant Recipients in Community Pharmacy: Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients
- ClinicalTrials.gov ID
- NCT06652919
- Acronym / sponsor ID
- Clinical Pharmacy Uni MS_2024
- Conditions
- Organ Transplantation
- Keywords
- Organ transplantation, Consumer Information Rating Form, Pharmaceutical Care, Community Pharmacy, Patient Information Leaflets
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Universität MünsterUniversity, hospital or other
- Study start
- 6 Nov 2024 (estimated)
- Primary completion
- Jan 2025 (estimated)
- Study completion
- Mar 2025 (estimated)
- First posted
- 22 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to collect feedback from organ transplant patients or their caregivers/relatives on the medication information leaflets we've developed, using a questionnaire, and to adjust the content to better meet the specific needs of this unique patient group.
Detailed description
Introduction:
Organ transplantation is a life-saving procedure, but it also marks the beginning of a lifelong journey for patients. In 2023 alone, over 3,600 organ transplants were performed in Germany, with kidney, liver, heart, and lung transplants being the most common. Following a transplant, patients must take a combination of immunosuppressive medications to prevent their body from rejecting the new organ. These drugs, while essential, come with significant risks. Many of which have a very narrow therapeutic range and a high risk of drug interactions. Additionally, these medications have unique side effects that can affect mortality and health-related quality of life (HRQOL). As a result, organ transplant patients require constant medical monitoring and comprehensive education about their medications to ensure long-term graft survival and a better quality of life.
Community pharmacies in Germany have recognized the need to support these patients. Since 2022, community pharmacies have been offering pharmaceutical care services specifically tailored to organ transplant recipients, focusing on safe medication use and personalized counseling, including brown-bag reviews. This service is covered by health insurance and aims to reduce administration errors, improve therapy adherence, and enhance overall patient safety. However, despite nearly 4,000 new organ transplants each year, only a small fraction of these patients-less than 3%-benefit from these services annually. The reality is that public pharmacies rarely interact with transplant patients, as they make up a small group. Furthermore, there is currently a lack of adequate materials to support the provision of this service for transplant patients.
This research project addresses this gap by developing and validating specific materials that will help pharmacies deliver high-quality pharmaceutical care to organ transplant recipients. A key element of this project is the medication information leaflets designed by the investigators, which aim to enhance patients' understanding of their immunosuppressive therapy, reduce medication use errors, and ultimately improve medication safety.
The aim of this study is to collect feedback from organ transplant patients or their caregivers/relatives on these medication leaflets, using a questionnaire instrument called "Adapted Consumer Information Rating Form (CIRF)", developed by Krass et al. The results will help the investigators evaluate the quality of the medication information leaflets in terms of their content and design. This will also assist the investigators in adjusting the content to better meet the specific needs of this unique patient group in the future.
Study design:
This pilot study is designed as a descriptive survey. It involves a one-time survey, either online or in paper form, that collects data on participants' evaluations and opinions regarding the medication information sheets. The instrument that is used, the original Adapted CIRF, was initially translated by the investigators through a peer review process, including cultural adaptation from English to German. After two rounds of peer review, the final version was produced. Permission for the use and translation of the original Adapted CIRF was obtained from Krass et al. Additionally, demographic data will be collected in the study. This study was approved by the Ethics Committee: Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster.
The recruitment of the participants will be conducted through cooperating pharmacies and patient self-help groups, and participation in the questionnaire is voluntary. Data protection measures will be taken into account to ensure the confidentiality and security of participants' information.
Procedure for participation in the study:
- The study begins as soon as the participants have agreed to the consent form.
- The study consists of two parts. In Part 1, participants are asked to select a medication information sheet and thoroughly read it.
- In Part 2, participants will ask to complete the questionnaire.
- After completing the questionnaire, the participation is considered finished. The process will take approximately 10 to 20 minutes.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who have undergone solid organ transplantation (kidney, liver, heart, lung) or their caregivers/family members
Key inclusion criteria (4 listed)
- Patients who have undergone solid organ transplantation (kidney, liver, heart, lung)
- Caregivers or family members of organ transplant patients
- German-speaking individuals
- adult
Key exclusion criteria (4 listed)
- Individuals who are not able to provide consent
- Non-German-speaking individuals
- under 18 years old
- Patients who have undergone organ transplantation and are no longer taking immunosuppressants
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Consumer Information Rating Form (CIRF): Mean "comprehensibility" score, mean "future use" score, mean "utility" score and mean "design quality" score.
Time frame: 3 months
In this research, the measurement instrument called the Consumer Information Rating Form (CIRF) is used, though the content has been slightly adapted to fit our study. It was developed as a direct method for quantifying consumers' perceptions of written patient information, including their views on its comprehensibility, utility, and overall design quality. In the questionnaire, four perspectives will be evaluated using Likert scales, including "comprehensibility" (5 items, with a total score range from 5 to 25), "future use" (3 items, with a total score range from 3 to 15), "utility" (5 topics with two perspectives: the amount of information provided and its usefulness, with a total score range from 3 to 20.), and "design quality" (6 items, with a total score range from 6 to 30). Higher scores indicate better quality of the patient information leaflet.
Participants' characteristics
Time frame: 3 months
Gender, age group, highest level of education, current employment status, if participant has worked in the healthcare system, Which patient information leaflet did the participant evaluate? What type of organ transplant has the participant or the person they look after received? (Kidney, liver, heart, or lung transplant), How long has it been since the transplant?
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Nov 2024.
Related trials for Organ Transplantation
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
Recruiting
Multidisciplinary Non-Pharmacological Intervention to Improve Quality of Life in Solid Organ Transplant Recipients
Heart Transplant Patients, Kidney Transplant Patients
RecruitingObservational study
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
End-stage Liver Disease (ESLD), Acute Liver Failure
Not yet recruitingObservational study
Brain-based Prediction of the Dying Duration in Humans After Withdrawal of Life Sustaining Therapies to Inform Donation After Circulatory Death
Organ Donation After Circulatory Death
Recruiting
In-situ vs Ex-situ Liver Preservation
Liver Disease (Alcoholic or Not), Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Organ Transplantation, run by Universität Münster at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Li-Yun Chen (+49 (0) 251 83-32173, liyun.chen@uni-muenster.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Consumer Information Rating Form (CIRF): Mean "comprehensibility" score, mean "future use" score, mean "utility" score and mean "design quality" score. (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2024.